Thursday 16 October, 2025
Objectives: Leflunomide is an immunosuppressive drug indicated for the treatment of rheumatoid arthritis (RA). Leflunomide is characterized by high protein…
Read moreAbstracts
Population pharmacokinetics of abiraterone in patients with metastatic castration resistant prostate cancer
Thursday 16 October, 2025
Introduction/Objectives: Abiraterone acetate is approved for the treatment of metastatic castration resistant prostate cancer (mCRPC) [1,2]. After oral administration, abiraterone…
Read moreA Generative Pre-trained Transformer for Time-Course and Dose-Response Predictions
Thursday 16 October, 2025
Objectives: Neural networks (NNs) constitute a class of artificial intelligence methods inspired by the human brain to teach computers to process…
Read morePharmacometrics Time-to-Event (TTE) Modeling of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients
Thursday 16 October, 2025
Objectives: Time-to-event (TTE) pharmacometrics analysis has an important role in the parametric quantification of the occurrence of diabetic nephropathy. Incorporating…
Read moreA paradigm shift in oral drug absorption: The rise of physiologically based finite time pharmacokinetic (PBFTPK) models.
Thursday 16 October, 2025
Objectives: To explore the application of the parameters of the physiologically based finite time pharmacokinetic (PBFTPK) models (1) subdivided in first-order…
Read moreRe-writing oral pharmacokinetics using physiologically based finite time pharmacokinetic (PBFTPK) models
Thursday 16 October, 2025
Objectives: The development of the Finite Absorption Time (FAT) concept for oral drug absorption was accomplished recently(1-4). These studies demonstrate…
Read moreA unifying approach to sampling NLME model parameters
Thursday 16 October, 2025
Objectives: Simulation of models is a key element of model diagnostics as well as a popular method for model-based prospective decision…
Read moreAn age-dependent QSP model of Nf trafficking to optimize treatment in neurodegenerative diseases
Thursday 16 October, 2025
Introduction: Neurofilament (Nf) has been identified as a potential biomarker for different neurodegenerative diseases, including SMA and ALS [1,2], and…
Read morePopulation pharmacokinetics of ritonavir-boosted darunavir in children aged 3 to 15 years in the CHAPAS 4 trial living with HIV in Africa.
Thursday 16 October, 2025
Introduction and Objectives: Darunavir is an antiretroviral drug from the class of protease inhibitors (PIs)[1]. It is typically boosted with…
Read moreA pooled pharmacokinetic analysis of rifampicin, isoniazid, and pyrazinamide in paediatric patients with tuberculosis.
Thursday 16 October, 2025
INTRODUCTION: HIV and tuberculosis (TB) co-infection is common in resource limited settings (1). There have been inconsistent findings on the…
Read more